ClinVar Miner

Submissions for variant NM_001042492.3(NF1):c.5687C>G (p.Ser1896Ter)

dbSNP: rs1135402879
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000497076 SCV000960648 pathogenic Neurofibromatosis, type 1 2023-07-22 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 431663). This premature translational stop signal has been observed in individual(s) with diagnosis of neurofibromatosis type 1 (PMID: 26458495). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Ser1875*) in the NF1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in NF1 are known to be pathogenic (PMID: 10712197, 23913538).
Ambry Genetics RCV002319507 SCV001186333 pathogenic Hereditary cancer-predisposing syndrome; Cardiovascular phenotype 2018-07-05 criteria provided, single submitter clinical testing The p.S1875* pathogenic mutation (also known as c.5624C>G), located in coding exon 38 of the NF1 gene, results from a C to G substitution at nucleotide position 5624. This changes the amino acid from a serine to a stop codon within coding exon 38. De novo occurrence of this mutation has been reported in an individual with suspected neurofibromatosis type 1 (Yao R et al. J. Dermatol., 2016 May;43:537-42). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
Genome-Nilou Lab RCV000497076 SCV002560140 pathogenic Neurofibromatosis, type 1 2022-03-15 criteria provided, single submitter clinical testing
Neuberg Centre For Genomic Medicine, NCGM RCV000497076 SCV004176409 pathogenic Neurofibromatosis, type 1 2023-03-01 criteria provided, single submitter clinical testing The stop gained c.5687C>G (p.Ser1896Ter) variant in the NF1 gene has been observed in individual(s) with diagnosis of neurofibromatosis type 1 (Yao, Ruen et al., 2016). This variant is novel in the gnomAD Exomes and 1000 Genomes. It is submitted to ClinVar as Pathogenic. This variant is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. The nucleotide change c.5687C>G in NF1 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. Loss of function variants have been previously reported to be disease causing. For these reasons, this variant has been classified as Pathogenic.
Medical Genetics, University of Parma RCV000497076 SCV000588807 pathogenic Neurofibromatosis, type 1 2017-02-02 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.